Molecular mechanism of vitamin D receptor action

Abstract. The vitamin D system is unique in that distinct calcium homeostatic functions and cell growth regulatory activities are mediated through a single ligand, calcitriol, acting through a specific receptor exhibiting ubiquitous tissue expression, the vitamin D receptor (VDR). The VDR is a member of a superfamily of nuclear steroid hormone receptors which regulate gene transcription by interacting with response elements in gene promoters. Structure-function analysis of the VDR protein has defined distinct domains involved in DNA binding, ligand binding, receptor dimerisation and gene transactivation, including a C-terminal activation function domain (AF-2) that is important for cofactor interaction. A model for regulation of gene transcription by the VDR is evolving and proposes VDR interaction with various components of the basal transcriptional machinery, including newly defined coactivators and corepressors, which may act to regulate gene transcription by altering histone acetylation and chromatin structure. This review describes the vitamin D endocrine system and the role of the VDR in regulating this system, including the molecular basis for the diverse actions of synthetic calcitriol analogues in the treatment of autoimmune disease and cancer.

[1]  K. Ozono,et al.  The vitamin D-responsive element in the human osteocalcin gene. Association with a nuclear proto-oncogene enhancer. , 1990, The Journal of biological chemistry.

[2]  D. Edwards,et al.  The Steroid Receptor Coactivator-1 Contains Multiple Receptor Interacting and Activation Domains That Cooperatively Enhance the Activation Function 1 (AF1) and AF2 Domains of Steroid Receptors* , 1998, The Journal of Biological Chemistry.

[3]  M. Bissonnette,et al.  1α,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a Noncalcemic Analogue of 1α,25-Dihydroxyvitamin D3, Inhibits Azoxymethane-induced Colonic Tumorigenesis , 1995 .

[4]  Jeffrey W. Clark,et al.  1α,25-dihydroxy-24-oxo-16-ene vitamin D3, a metabolite of a synthetic vitamin D3 analog, 1α,25-dihydroxy-16-ene vitamin D3, is equipotent to its parent in modulating growth and differentiation of human leukemic cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[5]  S. Fawell,et al.  Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. , 1993, Molecular endocrinology.

[6]  J. Eisman,et al.  Identification of a vitamin D3 response element in the fibronectin gene that is bound by a vitamin D3 receptor homodimer , 1996, Journal of cellular biochemistry.

[7]  H. DeLuca,et al.  Up-regulation of the vitamin D receptor in response to 1,25-dihydroxyvitamin D3 results from ligand-induced stabilization. , 1992, The Journal of biological chemistry.

[8]  J. Jones,et al.  Cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxyvitamin D3 in HL60 cells. , 1996, Cancer research.

[9]  C. Carlberg,et al.  Two nuclear signalling pathways for vitamin D , 1993, Nature.

[10]  H. DeLuca,et al.  Vitamin D deficiency suppresses cell-mediated immunity in vivo. , 1993, Archives of biochemistry and biophysics.

[11]  Daniel Metzger,et al.  Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase , 1995, Science.

[12]  M. Haussler,et al.  Association of 1,25-dihydroxyvitamin D3 with cultured 3T6 mouse fibroblasts. Cellular uptake and receptor-mediated migration to the nucleus. , 1983, The Journal of biological chemistry.

[13]  T. Kuroki,et al.  Regulation of Terminal Differentiation of Cultured Mouse Epidermal Cells by lα,25-Dihydroxyvitamin D3 , 1983 .

[14]  R. Kumar,et al.  Metabolism of 1,25-dihydroxyvitamin D3. , 1984, Physiological reviews.

[15]  P. Kushner,et al.  Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. , 1995, The EMBO journal.

[16]  W. Pike,et al.  Tissue specificity and mechanism of vitamin D receptor up‐regulation during dietary phosphorus restriction in the rat , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  C. Glass,et al.  Differential orientations of the DNA-binding domain and carboxy-terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers. , 1993, Genes & development.

[18]  M. Becich,et al.  1,25-Dihydroxy-16-ene-23-yne-vitamin D3 and prostate cancer cell proliferation in vivo. , 1995, Urology.

[19]  S. de Vos,et al.  Effects of potent vitamin D3 analogs on clonal proliferation of human prostate cancer cell lines , 1997, The Prostate.

[20]  Kevin Struhl,et al.  The TAFs in the HAT , 1998, Cell.

[21]  L. Dorssers,et al.  Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. , 1994, Cancer research.

[22]  B. Lewis A Historical Overview , 1996 .

[23]  M. Owen,et al.  Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia , 1997, Cell.

[24]  H. DeLuca,et al.  1α,25-dihydroxyvitamin D3 a nd 19-nor-1α,25-dihydroxyvitamin 32 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo , 1993 .

[25]  V. Chatterjee,et al.  Functional analysis of a transactivation domain in the thyroid hormone beta receptor. , 1994, The Journal of biological chemistry.

[26]  P. Lomedico,et al.  Vitamin D3-retinoid X receptor dimerization, DNA binding, and transactivation are differentially affected by analogs of 1,25-dihydroxyvitamin D3. , 1995, Molecular endocrinology.

[27]  Z. Su,et al.  Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. , 1994, Oncogene.

[28]  P. Brachet,et al.  1,25 Dihydroxyvitamin D3 Exerts Regional Effects in the Central Nervous System during Experimental Allergic Encephalomyelitis , 1996, Journal of neuropathology and experimental neurology.

[29]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.

[30]  E. Ritz,et al.  Synergistic effects of parathyroid hormone and 1,25-dihydroxyvitamin D3 on proliferation and vitamin D receptor expression of rat growth cartilage cells. , 1994, Endocrinology.

[31]  R. Uppaluri,et al.  Genetic dissection of thyroid hormone receptor beta: identification of mutations that separate hormone binding and transcriptional activation , 1995, Molecular and cellular biology.

[32]  M. Stallcup,et al.  GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Koeffler,et al.  Structure-function studies on analogues of 1 alpha,25-dihydroxyvitamin D3: differential effects on leukemic cell growth, differentiation, and intestinal calcium absorption. , 1990, Cancer research.

[34]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[35]  J. Pike,et al.  Human vitamin D receptor-dependent transactivation in Saccharomyces cerevisiae requires retinoid X receptor. , 1996, Molecular endocrinology.

[36]  H. Freund,et al.  Historical overview. , 2021, Advances in neurology.

[37]  P. Chambon,et al.  TIF2, a 160 kDa transcriptional mediator for the ligand‐dependent activation function AF‐2 of nuclear receptors. , 1996, The EMBO journal.

[38]  B. O’Malley,et al.  Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. , 1988, Science.

[39]  Tatsuya Yoshizawa,et al.  Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning , 1997, Nature Genetics.

[40]  M. Grunstein Histone acetylation in chromatin structure and transcription , 1997, Nature.

[41]  G. Chiocchia,et al.  Combination of cyclosporine A and calcitriol in the treatment of adjuvant arthritis. , 1992, The Journal of rheumatology.

[42]  A. Norman,et al.  Profile of ligand specificity of the vitamin D binding protein for 1α,25‐dihydroxyvitamin d3 and its analogs , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[43]  A. Berdal,et al.  Immunolocalization of Vitamin D Receptor and Calbindin-D28k in Human Tooth Germ , 1996, Pediatric Research.

[44]  X. Jacq,et al.  Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor , 1994, Cell.

[45]  F. Deschner,et al.  Relationship Between Disease Activity and Serum Levels of Vitamin D Metabolites and PTH in Rheumatoid Arthritis , 1998, Calcified Tissue International.

[46]  P. Chambon,et al.  Activation function 2 (AF‐2) of retinoic acid receptor and 9‐cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF‐2 activity. , 1994, The EMBO journal.

[47]  Thorsten Heinzel,et al.  Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor , 1995, Nature.

[48]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[49]  Andrew J. Bannister,et al.  The TAFII250 Subunit of TFIID Has Histone Acetyltransferase Activity , 1996, Cell.

[50]  O. Clausen,et al.  1,25‐dihydroxyvitamin D3 and the vitamin D analogue KH1060 induce hyperproliferation in normal mouse epidermis , 1993, Experimental dermatology.

[51]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[52]  H. DeLuca,et al.  Identification of a vitamin D-response element in the rat calcidiol (25-hydroxyvitamin D3) 24-hydroxylase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[53]  M. Haussler,et al.  Human vitamin D receptor phosphorylation by casein kinase II at Ser-208 potentiates transcriptional activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[54]  G. Cooper,et al.  Are vitamin D receptor polymorphisms associated with bone mineral density? A meta‐analysis , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[55]  M. Galligan,et al.  Examination of the Potential Functional Role of Conserved Cysteine Residues in the Hormone Binding Domain of the Human 1,25-Dihydroxyvitamin D Receptor (*) , 1996, The Journal of Biological Chemistry.

[56]  Thomas Shenk,et al.  TATA-binding protein-independent initiation: YY1, TFIIB, and RNA polymerase II direct basal transcription on supercoiled template DNA , 1994, Cell.

[57]  Philippe Kastner,et al.  Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently , 1992, Cell.

[58]  J. Eisman,et al.  Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin D3 metabolites. , 1983, Cancer research.

[59]  A. Norman,et al.  Metabolism of the cell differentiating agent 1α,25(OH)2-16-ene-23-yne vitamin D3 by leukemic cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[60]  J. Shine,et al.  1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. , 1989, Science.

[61]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.

[62]  A. Mackay,et al.  Vitamin D derivatives in combination with 9-cis retinoic acid promote active cell death in breast cancer cells. , 1995, Journal of molecular endocrinology.

[63]  B. Katzenellenbogen,et al.  Powerful dominant negative mutants of the human estrogen receptor. , 1993, The Journal of biological chemistry.

[64]  K. Kristjánsson,et al.  Two mutations causing vitamin D resistant rickets: modelling on the basis of steroid hormone receptor DNA‐binding domain crystal structures , 1994, Clinical endocrinology.

[65]  Henderson Nk,et al.  Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone , 1996, Current opinion in rheumatology.

[66]  H. DeLuca,et al.  Cloning of the human 1 alpha,25-dihydroxyvitamin D-3 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. , 1995, Biochimica et biophysica acta.

[67]  P. Goldberg Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence. (A viewpoint). Part 1. Sunlight, dietary factors and epidemiology. , 1974 .

[68]  A. Norman,et al.  1 alpha,25(OH)2 vitamin D3-regulated expression of the eukaryotic genome. , 1994, Nutrition reviews.

[69]  S. Cramer,et al.  Regulation of 1,25-dihydroxyvitamin D3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways. , 1995, Endocrinology.

[70]  S. Minucci,et al.  The histone acetylase PCAF is a nuclear receptor coactivator. , 1998, Genes & development.

[71]  D. Peehl,et al.  Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. , 1993, Endocrinology.

[72]  R. Gniadecki,et al.  Stimulation of epidermal proliferation in mice with 1 alpha, 25-dihydroxyvitamin D3 and receptor-active 20-EPI analogues of 1 alpha, 25-dihydroxyvitamin D3. , 1995, Biochemical pharmacology.

[73]  B. O’Malley,et al.  Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). , 1992, The Journal of biological chemistry.

[74]  M. Sporn,et al.  1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531), a new deltanoid (vitamin D analogue) for prevention of breast cancer in the rat. , 1994, Cancer research.

[75]  Jun Qin,et al.  Histone-like TAFs within the PCAF Histone Acetylase Complex , 1998, Cell.

[76]  M. Bissonnette,et al.  1 alpha,25-Dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol, a noncalcemic analogue of 1 alpha,25-dihydroxyvitamin D3, inhibits azoxymethane-induced colonic tumorigenesis. , 1995, Cancer research.

[77]  J. Eisman,et al.  Human and murine osteocalcin gene expression: conserved tissue restricted expression and divergent responses to 1,25-dihydroxyvitamin D3 in vivo. , 1997, Molecular endocrinology.

[78]  D. Feldman,et al.  The role of vitamin D3 in immunosuppression: lessons from autoimmunity and transplantation. , 1997 .

[79]  M. Haussler,et al.  Chromosomal Receptor for A Vitamin D Metabolite , 1969 .

[80]  R. Gniadecki,et al.  Stimulation of epidermal proliferation in mice with 1α,25-dihydroxyvitamin D3 and receptor-active 20-epi analogues of 1α,25-dihydroxyvitamin D3 , 1995 .

[81]  R. Kremer,et al.  In Vitro Metabolism of the Vitamin D Analog, 22-Oxacalcitriol, Using Cultured Osteosarcoma, Hepatoma, and Keratinocyte Cell Lines (*) , 1996, The Journal of Biological Chemistry.

[82]  M. Haussler,et al.  Transcription factor TFIIB and the vitamin D receptor cooperatively activate ligand-dependent transcription. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[83]  A. Mackay,et al.  Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[84]  G. Whitfield "A highly conserved region in the hormone-binding domain of the human vitamin D receptor contains residues vital for heterodimerization with retinoid X receptor and for transcriptional activation". , 1995, Molecular endocrinology.

[85]  B. O’Malley,et al.  Mutant vitamin D receptors which confer hereditary resistance to 1,25-dihydroxyvitamin D3 in humans are transcriptionally inactive in vitro. , 1989, The Journal of biological chemistry.

[86]  L. Binderup,et al.  20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. , 1991, Biochemical pharmacology.

[87]  S. Collins,et al.  The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression. , 1987, Blood.

[88]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[89]  H. DeLuca,et al.  Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediate transcriptional repression in response to 1,25-dihydroxyvitamin D3. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[90]  H. DeLuca,et al.  Two Vitamin D Response Elements Function in the Rat 1,25-Dihydroxyvitamin D 24-Hydroxylase Promoter (*) , 1995, The Journal of Biological Chemistry.

[91]  J. Eisman,et al.  Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[92]  Y. Liu,et al.  Vitamin D Receptors Repress Basal Transcription and Exert Dominant Negative Activity on Triiodothyronine-mediated Transcriptional Activity (*) , 1996, The Journal of Biological Chemistry.

[93]  H. Erdjument-Bromage,et al.  A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. , 1998, Genes & development.

[94]  S. Teitelbaum,et al.  Competition for a Unique Response Element Mediates Retinoic Acid Inhibition of Vitamin D3-stimulated Transcription* , 1996, The Journal of Biological Chemistry.

[95]  P. Sambrook,et al.  Relationship between osteoporosis and arthritis and effect of corticosteroids and other drugs on bone , 1996, Current opinion in rheumatology.

[96]  M. Haussler,et al.  Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. , 1988, Endocrinology.

[97]  P. N. MacDonald,et al.  The N-terminal domain of transcription factor IIB is required for direct interaction with the vitamin D receptor and participates in vitamin D-mediated transcription. , 1997, Molecular endocrinology.

[98]  C. Carlberg,et al.  The high affinity ligand binding conformation of the nuclear 1,25-dihydroxyvitamin D3 receptor is functionally linked to the transactivation domain 2 (AF-2). , 1996, Nucleic acids research.

[99]  B. O’Malley,et al.  Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. , 1989, Molecular endocrinology.

[100]  M. Haussler,et al.  Novel nuclear localization signal between the two DNA‐binding zinc fingers in the human vitamin D receptor , 1998, Journal of cellular biochemistry.

[101]  D. Sherman,et al.  The Vitamin D Receptor Interacts with General Transcription Factor IIB (*) , 1995, The Journal of Biological Chemistry.

[102]  L. Freedman,et al.  DNA sequences that act as high affinity targets for the vitamin D3 receptor in the absence of the retinoid X receptor. , 1994, Molecular endocrinology.

[103]  I. Wang,et al.  Interaction between the Retinoid X Receptor and Transcription Factor IIB Is Ligand-dependent in Vivo * , 1998, The Journal of Biological Chemistry.

[104]  S. Krane,et al.  Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. , 1986, Cellular immunology.

[105]  J. Shine,et al.  ApaI dimorphism at the human vitamin D receptor gene locus. , 1989, Nucleic acids research.

[106]  R. Kageyama,et al.  Helix-loop-helix-type transcription factor (HES-1) is expressed in osteoblastic cells, suppressed by 1,25(OH)2 vitamin D3, and modulates 1,25(OH)2 vitamin D3 enhancement of osteopontin gene expression. , 1997, Bone.

[107]  M. Waugh,et al.  Decreased accessory cell function and costimulatory activity by 1,25-dihydroxyvitamin D3-treated monocytes. , 1992, Arthritis and rheumatism.

[108]  H. DeLuca,et al.  Cloning and origin of the two forms of chicken vitamin D receptor. , 1997, Archives of Biochemistry and Biophysics.

[109]  P. Andrew,et al.  1α,25-Dihydroxyvitamin D3 and a Variety of its Natural Metabolites Transcriptionally Repress Nuclear-Factor-κB-Mediated Interleukin-8 Gene Expression , 1997 .

[110]  E. Wagner,et al.  c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. , 1995, Cancer research.

[111]  C. Mathieu,et al.  Prevention of type I diabetes by late intervention with nonhypercalcemic analogues of vitamin D3 in combination with cyclosporin A. , 1996, Transplantation proceedings.

[112]  F. Glorieux,et al.  The 25‐Hydroxyvitamin D 1‐Alpha‐Hydroxylase Gene Maps to the Pseudovitamin D‐Deficiency Rickets (PDDR) Disease Locus , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[113]  A. Norman,et al.  Differential Interaction of 1α,25-Dihydroxyvitamin D3 Analogues and Their 20-epi Homologues with the Vitamin D Receptor* , 1997, The Journal of Biological Chemistry.

[114]  L. Freedman,et al.  Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. , 1996, Genes & development.

[115]  J. Reichrath,et al.  Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin. , 1997, Journal of the American Academy of Dermatology.

[116]  M. Garabedian,et al.  GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors , 1997, Molecular and cellular biology.

[117]  P. Chambon,et al.  Stimulation of RARα Activation Function AF-1 through Binding to the General Transcription Factor TFIIH and Phosphorylation by CDK7 , 1997, Cell.

[118]  S. Krane,et al.  Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. , 1983, The Journal of clinical endocrinology and metabolism.

[119]  J. Pike,et al.  Hormone-dependent phosphorylation of the 1,25-dihydroxyvitamin D3 receptor in mouse fibroblasts. , 1985, Biochemical and biophysical research communications.

[120]  H. DeLuca,et al.  Immunocytology with microwave-fixed fibroblasts shows 1 alpha,25- dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors , 1990, The Journal of cell biology.

[121]  H. Koeffler,et al.  Structure-Function Studies on Analogues of 1α,25-Dihydroxyvitamin D3: Differential Effects on Leukemic Cell Growth, Differentiation, and Intestinal Calcium Absorption , 1990 .

[122]  M. Becker‐André,et al.  Interaction between retinoic acid and vitamin D signaling pathways. , 1993, The Journal of biological chemistry.

[123]  H. DeLuca,et al.  Vitamin D-dependency rickets type II: truncated vitamin D receptor in three kindreds , 1993, Molecular and Cellular Endocrinology.

[124]  S. de Vos,et al.  20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. , 1995, Cancer research.

[125]  M. Galligan,et al.  The C-terminal region of the vitamin D receptor is essential to form a complex with a receptor auxiliary factor required for high affinity binding to the vitamin D-responsive element. , 1994, Molecular endocrinology.

[126]  K. Kristjánsson,et al.  Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. , 1993, The Journal of clinical investigation.

[127]  Anthony W. Norman,et al.  Vitamin D : chemistry, biology and clinical applications of the steroid hormone : proceedings of the Tenth Workshop on Vitamin D, Strasbourg, France, May 24-29, 1997 , 1997 .

[128]  M. Galligan,et al.  Vitamin D receptors from patients with resistance to 1,25-dihydroxyvitamin D3: point mutations confer reduced transactivation in response to ligand and impaired interaction with the retinoid X receptor heterodimeric partner. , 1996, Molecular endocrinology.

[129]  M. Haussler,et al.  Inhibition of ligand induced promoter occupancy in vivo by a dominant negative RXR , 1996, Genes to cells : devoted to molecular & cellular mechanisms.

[130]  G. Reddy,et al.  1,25-Dihydroxy-24-OXO-16ene-vitamin D3, a renal metabolite of the vitamin D analog 1,25-dihydroxy-16ene-vitamin D3, exerts immunosuppressive activity equal to its parent without causing hypercalcemia in vivo. , 1994, Endocrinology.

[131]  R. Bouillon,et al.  Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. , 1997, The Journal of clinical investigation.

[132]  L. Freedman,et al.  Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. , 1999, The Journal of nutrition.

[133]  G. Martin,et al.  Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription. , 1994, Science.

[134]  Bernhard Lüscher,et al.  Characterization of the Transcriptional Regulator YY1 , 1997, The Journal of Biological Chemistry.

[135]  J. Pike,et al.  Vitamin D receptor interaction with specific DNA. Association as a 1,25-dihydroxyvitamin D3-modulated heterodimer. , 1991, The Journal of biological chemistry.

[136]  L. Freedman Anatomy of the steroid receptor zinc finger region. , 1992, Endocrine reviews.

[137]  M. Campbell,et al.  Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin. , 1997, Journal of molecular endocrinology.

[138]  H. DeLuca,et al.  Vitamin D and Multiple Sclerosis , 1997, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[139]  H. Sakagami,et al.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[140]  K. Kragballe Calcipotriol: a new drug for topical psoriasis treatment. , 1995, Pharmacology & toxicology.

[141]  L. Binderup,et al.  Metabolism of the vitamin D analog EB 1089: identification of in vivo and in vitro liver metabolites and their biological activities. , 1997, Biochemical pharmacology.

[142]  M. Karin,et al.  Altering the specificity of signal transduction cascades: positive regulation of c‐Jun transcriptional activity by protein kinase A. , 1994, The EMBO journal.

[143]  D. Bikle,et al.  Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells. , 1996, Cancer research.

[144]  M. Lazar Thyroid hormone receptors: multiple forms, multiple possibilities. , 1993, Endocrine reviews.

[145]  H. DeLuca,et al.  1,25-Dihydroxyvitamin D in biological fluids: a simplified and sensitive assay. , 1976, Science.

[146]  B. Frenkel,et al.  YY1 regulates vitamin D receptor/retinoid X receptor mediated transactivation of the vitamin D responsive osteocalcin gene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[147]  M. Haussler,et al.  The 1,25-dihydroxy-vitamin D3 receptor is phosphorylated in response to 1,25-dihydroxy-vitamin D3 and 22-oxacalcitriol in rat osteoblasts, and by casein kinase II, in vitro. , 1993, Biochemistry.

[148]  M. Montminy,et al.  Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.

[149]  B. Howard,et al.  A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A , 1996, Nature.

[150]  P. Price,et al.  Ligand-dependent regulation of the 1,25-dihydroxyvitamin D3 receptor in rat osteosarcoma cells. , 1987, The Journal of biological chemistry.

[151]  Hueng-Sik Choi,et al.  Steroid Receptor Coactivator-1 Interacts with the p50 Subunit and Coactivates Nuclear Factor κB-mediated Transactivations* , 1998, The Journal of Biological Chemistry.

[152]  P. Brachet,et al.  1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. , 1997, Brain research. Molecular brain research.

[153]  R. Cook,et al.  1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. , 1994, Biochemistry.

[154]  J. Eisman,et al.  Prediction of bone density from vitamin D receptor alleles , 1994, Nature.

[155]  D. Heber,et al.  and Inducers of Differentiation of Human Breast Cancer Cell Lines , 1995 .

[156]  A. Turner,et al.  Safety and efficacy of oral calcitriol (1, 25 ‐dihydroxyvitamin D3) for the treatment of psoriasis , 1996, The British journal of dermatology.

[157]  D. Feldman,et al.  Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. , 1993, Endocrinology.

[158]  K. Meerovitch,et al.  Identification and Characterization of 1,25-Dihydroxyvitamin D3-responsive Repressor Sequences in the Rat Parathyroid Hormone-related Peptide Gene* , 1996, The Journal of Biological Chemistry.

[159]  L. Freedman,et al.  Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor , 1995, Molecular and cellular biology.

[160]  Ames,et al.  Vitamin D-receptor gene polymorphisms and bone density in prepubertal American girls of Mexican descent. , 1997, The New England journal of medicine.

[161]  P. Chambon,et al.  The dimerization interfaces formed between the DNA binding domains of RXR, RAR and TR determine the binding specificity and polarity of the full‐length receptors to direct repeats. , 1994, The EMBO journal.

[162]  H. DeLuca,et al.  1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[163]  Hui Li,et al.  RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[164]  S. Wölfl,et al.  L7 protein is a coregulator of vitamin D receptor‐retinoid X receptor‐mediated transactivation , 1998, Journal of cellular biochemistry.

[165]  M. Parker,et al.  Interaction of proteins with transcriptionally active estrogen receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[166]  F. Révillion,et al.  Vitamin‐D3 derivatives and breast‐tumor cell growth: Effect on intracellular calcium and apoptosis , 1995, International journal of cancer.

[167]  A. Wolffe,et al.  Histone acetylation: chromatin in action. , 1997, Trends in biochemical sciences.

[168]  K. Umesono,et al.  Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.

[169]  A. Norman,et al.  Distinct Conformational Changes Induced by 20-epi Analogues of 1,25-Dihydroxyvitamin D Are Associated with Enhanced Activation of the Vitamin D Receptor (*) , 1995, The Journal of Biological Chemistry.

[170]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[171]  S. Teitelbaum,et al.  Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1,25-dihydroxyvitamin D3. , 1993, The Journal of biological chemistry.

[172]  D. Feldman,et al.  Cyclic adenosine 3',5'-monophosphate up-regulates 1,25-dihydroxyvitamin D3 receptor gene expression and enhances hormone action. , 1992, Molecular endocrinology.

[173]  T. Baudino,et al.  Isolation and Characterization of a Novel Coactivator Protein, NCoA-62, Involved in Vitamin D-mediated Transcription* , 1998, The Journal of Biological Chemistry.

[174]  J. Levy,et al.  Evidence that estrogens modulate activity and increase the number of 1,25-dihydroxyvitamin D receptors in osteoblast-like cells (ROS 17/2.8). , 1992, Endocrinology.

[175]  J. Y. Chen,et al.  Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently. , 1992, Cell.

[176]  E. Appella,et al.  H‐2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes. , 1992, The EMBO journal.

[177]  M. Haussler,et al.  New insight into the structure and functions of the vitamin D receptor. , 1994, Seminars in nephrology.

[178]  J. Williams,et al.  Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. , 1995, Anti-cancer drugs.

[179]  R. Roeder,et al.  The TRAP220 component of a thyroid hormone receptor- associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[180]  J. Eisman,et al.  Regulation of the 1,25-dihydroxyvitamin D3 receptor by 1,25-dihydroxyvitamin D3 in intact human cancer cells. , 1985, Endocrinology.

[181]  M. Haussler,et al.  Molecular cloning of complementary DNA encoding the avian receptor for vitamin D. , 1987, Science.

[182]  J. Shine,et al.  Cloning and expression of full-length cDNA encoding human vitamin D receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[183]  D. Bikle,et al.  Cloning of the Human Phospholipase C-γ1 Promoter and Identification of a DR6-type Vitamin D-responsive Element* , 1997, The Journal of Biological Chemistry.

[184]  I. Reid,et al.  Parathyroid hormone-related protein-(107-139) inhibits bone resorption in vivo. , 1997, Endocrinology.

[185]  H. DeLuca,et al.  The Sp1 transcription factor gene (SP1) and the 1,25-dihydroxyvitamin D3 receptor gene (VDR) are colocalized on human chromosome arm 12q and rat chromosome 7. , 1991, Genomics.

[186]  B. O’Malley,et al.  An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[187]  J. Eisman,et al.  1,25-Dihydroxyvitamin D3 and the Regulation of Human Cancer Cell Replication 1 , 1989, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[188]  H. DeLuca,et al.  1 alpha, 25-Dihydroxyvitamin D3 and 19-nor-1 alpha, 25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. , 1993, Biochimica et biophysica acta.

[189]  T. Stamey,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.

[190]  R. Schwartz Sunlight—Can it prevent as well as cause cancer? , 1996 .

[191]  J. Gustafsson,et al.  A regulatory role for RIP140 in nuclear receptor activation. , 1998, Molecular endocrinology.

[192]  C. Bunce,et al.  Treatment of HL60 cells with various combinations of retinoids and 1 alpha,25 dihydroxyvitamin D3 results in differentiation towards neutrophils or monocytes or a failure to differentiate and apoptosis. , 1995, Leukemia.

[193]  R. Mason,et al.  Human melanocytes as a target tissue for hormones: in vitro studies with 1 alpha-25, dihydroxyvitamin D3, alpha-melanocyte stimulating hormone, and beta-estradiol. , 1988, The Journal of investigative dermatology.

[194]  Allan Bradley,et al.  Increased bone formation in osteocalcin-deficient mice , 1996, Nature.

[195]  H. DeLuca,et al.  Identification of a DNA sequence responsible for binding of the 1,25-dihydroxyvitamin D3 receptor and 1,25-dihydroxyvitamin D3 enhancement of mouse secreted phosphoprotein 1 (SPP-1 or osteopontin) gene expression. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[196]  L. M. Atkins,et al.  Mapping the domains of the interaction of the vitamin D receptor and steroid receptor coactivator-1. , 1998, Molecular endocrinology.

[197]  B. O’Malley,et al.  Mouse retinoid X receptor contains a separable ligand-binding and transactivation domain in its E region , 1995, Molecular and cellular biology.

[198]  P. Brachet,et al.  1,25-dihydroxyvitamin D3 regulates the synthesis of nerve growth factor in primary cultures of glial cells. , 1994, Brain research. Molecular brain research.

[199]  A. Aranda,et al.  Vitamin D interferes with transactivation of the growth hormone gene by thyroid hormone and retinoic acid , 1996, Molecular and cellular biology.

[200]  A. Norman,et al.  Factors affecting the distribution and stability of unoccupied 1,25-dihydroxyvitamin D3 receptors. , 1981, Journal of receptor research.

[201]  H. DeLuca,et al.  Phosphorylation is involved in transcriptional activation by the 1,25-dihydroxyvitamin D3 receptor. , 1993, Biochimica et biophysica acta.

[202]  R. Mason,et al.  Human Melanocytes as a Target Tissue for Hormones: In Vitro Studies with 1α-25, dihydroxyvitamin D3, α-melanocyte Stimulating Hormone, and Beta-estradiol , 1988 .

[203]  H. DeLuca,et al.  Stabilization of the vitamin D receptor in rat osteosarcoma cells through the action of 1,25-dihydroxyvitamin D3. , 1993, Molecular endocrinology.

[204]  R. Mehta,et al.  Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. , 1997, Journal of the National Cancer Institute.

[205]  K. Umesono,et al.  Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene , 1990, Cell.

[206]  D. Ledbetter,et al.  Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13–14 , 1992, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[207]  R. Evans,et al.  A transcriptional co-repressor that interacts with nuclear hormone receptors , 1995, Nature.

[208]  L. Rorke,et al.  In vivo expression of inducible nitric oxide synthase in experimentally induced neurologic diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[209]  Raoul C. M. Hennekam,et al.  Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP , 1995, Nature.

[210]  Christopher K. Glass,et al.  The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function , 1997, Nature.

[211]  M. Haussler,et al.  New understanding of the molecular mechanism of receptor-mediated genomic actions of the vitamin D hormone. , 1995, Bone.

[212]  K. Ozono,et al.  Functional Assessment of Two Vitamin D-responsive Elements in the Rat 25-Hydroxyvitamin D3 24-Hydroxylase Gene* , 1996, The Journal of Biological Chemistry.

[213]  R. Bouillon,et al.  Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 α, 25-(OH)2D3 , 1995, Journal of Neuroimmunology.

[214]  C. Hahn,et al.  Transcriptional Synergism between Vitamin D-responsive Elements in the Rat 25-Hydroxyvitamin D3 24-Hydroxylase (CYP24) Promoter* , 1996, The Journal of Biological Chemistry.

[215]  P. Kerkhof,et al.  Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long‐term treatment with the vitamin D3 analogue MC903: modulations and interrelations , 1991 .

[216]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[217]  F. Dilworth,et al.  Increased biological activity of 20-epi-1,25-dihydroxyvitamin D3 is due to reduced catabolism and altered protein binding. , 1994, Biochemical pharmacology.

[218]  G. Rodan,et al.  The Missing Bone , 1997, Cell.

[219]  E. Slatopolsky,et al.  The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands. , 1995, Endocrinology.

[220]  R. Wernyj,et al.  Genomic mechanisms involved in the pleiotropic actions of 1,25-dihydroxyvitamin D3. , 1996, The Biochemical journal.

[221]  R. Bouillon,et al.  Enhancement of antiproliferative activity of 1α,25-dihydroxyvitamin D3 (analogs) by cytochrome P450 enzyme inhibitors is compound- and cell-type specific , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[222]  H. DeLuca,et al.  Id gene expression and its suppression by 1,25-dihydroxyvitamin D3 in rat osteoblastic osteosarcoma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[223]  J. Barsony,et al.  Subcellular Distribution of Normal and Mutant Vitamin D Receptors in Living Cells , 1997, The Journal of Biological Chemistry.

[224]  J. Welsh Induction of apoptosis in breast cancer cells in response to vitamin D and antiestrogens. , 1994, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[225]  I. Yokota,et al.  A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. , 1991, American journal of human genetics.

[226]  L. Freedman,et al.  Ligand modulates the conversion of DNA-bound vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers , 1994, Molecular and cellular biology.

[227]  M. Holick,et al.  Efficacy and safety of topical calcitriol (1,25‐dihydroxyvitamin D3) for the treatment of psoriasis , 1996, The British journal of dermatology.

[228]  P. Malloy,et al.  Hereditary 1 alpha,25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. , 1994, The Journal of clinical endocrinology and metabolism.

[229]  M. Cippitelli,et al.  Inhibition of IL-12 production by 1,25-dihydroxyvitamin D3. Involvement of NF-kappaB downregulation in transcriptional repression of the p40 gene. , 1998, The Journal of clinical investigation.

[230]  H. DeLuca,et al.  1,25-Dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. , 1998, The Journal of nutrition.

[231]  Y. Masuhiro,et al.  Transcriptional activity of a fluorinated vitamin D analog on VDR-RXR-mediated gene expression. , 1995, Biochemistry.

[232]  M. Haussler,et al.  Mutations in the 1,25-Dihydroxyvitamin D3 Receptor Identifying C-terminal Amino Acids Required for Transcriptional Activation That Are Functionally Dissociated from Hormone Binding, Heterodimeric DNA Binding, and Interaction with Basal Transcription Factor IIB, in Vitro * , 1997, The Journal of Biological Chemistry.

[233]  E. Rosen,et al.  Dimerization interfaces of thyroid hormone, retinoic acid, vitamin D, and retinoid X receptors. , 1993, The Journal of biological chemistry.

[234]  H. Jüppner,et al.  Cloning and characterization of the vitamin D receptor from Xenopus laevis. , 1997, Endocrinology.

[235]  Y. Miyamoto,et al.  Regulation of vitamin D-responsive gene expression by fluorinated analogs of calcitriol in rat osteoblastic ROB-C26 cells. , 1995, Journal of biochemistry.

[236]  P. Harnden,et al.  Immunocytochemical detection of a reduction in 1,25 dihyroxyvitamin D3 receptor expression in uraemic parathyroid tissue. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[237]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[238]  K. Kragballe,et al.  The vitamin D3 analog calcipotriol suppresses the number and antigen-presenting function of Langerhans cells in normal human skin. , 1996, The journal of investigative dermatology. Symposium proceedings.

[239]  P. Chambon,et al.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. , 1995, Nature.

[240]  J. Eisman,et al.  1α,25‐Dihydroxyvitamin D3 receptor as a mediator of transrepression of retinoid signaling , 1997 .

[241]  D. Feldman,et al.  Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. , 1980, The Journal of clinical endocrinology and metabolism.

[242]  Mary E. McGrath,et al.  A structural role for hormone in the thyroid hormone receptor , 1995, Nature.

[243]  B. Spiegelman,et al.  Pleiotropic effects of a null mutation in the c-fos proto-oncogene , 1992, Cell.

[244]  R. Bouillon,et al.  Vitamin D analogs with low affinity for the vitamin D binding protein: Enhanced in vitro and decreased in vivo activity , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[245]  C. Glass,et al.  Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding , 1994, Nature.

[246]  J. Weissenbach,et al.  Linkage disequilibrium analysis in young populations: pseudo-vitamin D-deficiency rickets and the founder effect in French Canadians. , 1996, American journal of human genetics.

[247]  P. Chambon,et al.  Human TAF(II)135 potentiates transcriptional activation by the AF-2s of the retinoic acid, vitamin D3, and thyroid hormone receptors in mammalian cells. , 1997, Genes & development.

[248]  J. Pike,et al.  Sequence elements in the human osteocalcin gene confer basal activation and inducible response to hormonal vitamin D3. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[249]  J M Lemire,et al.  1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. , 1991, The Journal of clinical investigation.

[250]  M. Galligan,et al.  Phosphorylation of the human vitamin D receptor by protein kinase C. Biochemical and functional evaluation of the serine 51 recognition site. , 1993, The Journal of biological chemistry.

[251]  J. Adams,et al.  1 alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. , 1984, The Journal of clinical investigation.

[252]  B. Komm,et al.  Molecular biology of the vitamin D hormone. , 1988, Recent progress in hormone research.

[253]  C. Carlberg,et al.  Identification of a vitamin D receptor homodimer-type response element in the rat calcitriol 24-hydroxylase gene promoter. , 1994, Biochemical and biophysical research communications.

[254]  J. Geysen,et al.  Proliferation and differentiation of cultured human keratinocytes is modulated by 1,25(OH)2D3 and synthetic vitamin D3 analogues in a cell density-, calcium- and serum-dependent manner. , 1997, Pharmacology & toxicology.

[255]  H. Koeffler,et al.  Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. , 1991, Blood.

[256]  J. Eisman,et al.  Significance of 1,25-dihydroxyvitamin D3 receptor in primary breast cancers. , 1986, Cancer research.

[257]  C. Mathieu,et al.  Prevention of diabetes recurrence after syngeneic islet transplantation in NOD mice by analogues of 1,25(OH)2D3 in combination with cyclosporin A: mechanism of action involves an immune shift from Th1 to Th2. , 1998, Transplantation proceedings.

[258]  C. Allis,et al.  Steroid receptor coactivator-1 is a histone acetyltransferase , 1997, Nature.

[259]  R. Horst,et al.  Intracellular location of unoccupied 1,25-dihydroxyvitamin D receptors: a nuclear-cytoplasmic equilibrium. , 1986, Archives of biochemistry and biophysics.

[260]  H. Yamamoto,et al.  Structural organization of the human vitamin D receptor chromosomal gene and its promoter. , 1997, Molecular endocrinology.

[261]  S. Mundlos,et al.  Cbfa1, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development , 1997, Cell.

[262]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[263]  M. Favus,et al.  Structure-function relationship of human parathyroid hormone in the regulation of vitamin D receptor expression in osteoblast-like cells (ROS 17/2.8). , 1995, Endocrinology.

[264]  B. O’Malley,et al.  Sequence and Characterization of a Coactivator for the Steroid Hormone Receptor Superfamily , 1995, Science.

[265]  C. Glass Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers. , 1994, Endocrine reviews.

[266]  J. Eisman,et al.  Whole-cell uptake and nuclear localization of 1,25-dihydroxycholecalciferol by breast cancer cells (T47 D) in culture. , 1981, The Biochemical journal.

[267]  L. Freedman,et al.  Retinoid X receptor:vitamin D3 receptor heterodimers promote stable preinitiation complex formation and direct 1,25-dihydroxyvitamin D3-dependent cell-free transcription , 1997, Molecular and cellular biology.

[268]  J. Pike,et al.  Transcriptional activation and dimerization functions in the human vitamin D receptor. , 1996, Molecular endocrinology.

[269]  H. Samuels,et al.  Interactions among a subfamily of nuclear hormone receptors: the regulatory zipper model. , 1990, Molecular endocrinology.

[270]  T. Martin,et al.  Expression of parathyroid hormone‐related protein in cells of osteoblast lineage , 1996, Journal of cellular physiology.

[271]  R. St-Arnaud,et al.  Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. , 1997, Molecular endocrinology.

[272]  C. Glass,et al.  Nuclear receptor coactivators. , 2000, Advances in pharmacology.

[273]  C. Glass,et al.  Multiple cell type-specific proteins differentially regulate target sequence recognition by the α retinoic acid receptor , 1990, Cell.

[274]  S. de Vos,et al.  1,25(OH)2-16ene-vitamin D3 is a potent antileukemic agent with low potential to cause hypercalcemia. , 1994, Leukemia research.

[275]  L. Freedman,et al.  Identification of a vitamin D3-response element that overlaps a unique inverted TATA box in the rat bone sialoprotein gene. , 1996, The Biochemical journal.

[276]  P. Chambon,et al.  Purification, functional characterization, and crystallization of the ligand binding domain of the retinoid X receptor. , 1995, Protein expression and purification.